ClinicalTrials.gg
RecruitingNCT06732531Updated Jan 9, 2025

Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer

A Phase 1/2 interventional study of BH011 in Bladder Cancer and Non Muscle Invasive, sponsored by Zhuhai Beihai Biotech Co., Ltd. Recruiting at 6 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-09.

Sponsored by Zhuhai Beihai Biotech Co., Ltd · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Registered 2 years 4 months after the study started (first participant enrolled Aug 2022, registered Dec 2024).
  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing docetaxel in Urinary Bladder Neoplasms — 5 open to participants now, 9 under way, none of them phase 3. Docetaxel · Urinary Bladder Neoplasms.

Planned enrollment
4th of 18
48 · median 31
Started
2022
the only one that year
Phase 1/2
3 of 20
2 open now
Registered
19th of 20
by date

Among the 20 studies testing docetaxel in Urinary Bladder Neoplasms, this one is the 4th largest by planned enrollment of the 18 interventional ones that give a count, is the only one that started in 2022, is one of 3 in phase 1/2, and was the 19th registered.

Urinary Bladder Neoplasms

1,800 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

5 of the 20 studies testing docetaxel in Urinary Bladder Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About docetaxel

Docetaxel: first FDA approval 1996 (TAXOTERE), first EMA approval 1995. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 336 Urinary Bladder Neoplasms studies recruiting now, 256 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing docetaxel in Urinary Bladder Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and tolerability of intravesical BH011 in patients with high-risk non-muscle invasive bladder cancer(NMIBC) after Bacillus Calmette-Guerin(BCG) failure and to assess the preliminary efficacy.

Read the detailed description

The plan is to study the safety and preliminary efficacy of BH011 in High-Risk NMIBC patients who failed BCG therapy. Most patients with NMIBC is (Cis, Cis with Ta and/or T1, high grade Ta or T1 with frequent or uncontrolled recurrences) who have failed BCG intravesical therapy (standard of care) usually have no other choice but to proceed to cystectomy. Cystectomy is a surgery associated with major morbidity, mortality and quality of life issues. Morbidity and long term tedious medical care will be for the rest of the patient's life span. Most patients at this stage do not show signs of disease progression into the muscle layer or of metastasis, making surgery a very difficult decision. BH011 will serve to provide a therapeutic alternative for this patient population in need.

In this study, patients will begin treatment with BH011 2-8 weeks after TURBT and will be administered once weekly for 6 weeks during the induction treatment period and once monthly for 12 months in the maintenance treatment period. Patients will undergo cystoscopy, urine cytology, and biopsy every 3 months for up to 24 months to confirm clinical efficacy.

03

Conditions studied

  • Bladder Cancer
  • Non Muscle Invasive

Keywords

  • BH011
  • High-Risk Non-Muscle-Invasive Bladder Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects were fully informed about the study and voluntarily signed an form and were willing to complete the trial in accordance with the protocol process.
  2. Male or female, ≥18 years of age at time of informed consent.
  3. First TURBT completed within 12 weeks prior to the first dose, confirmed diagnosis of non-muscle invasive bladder cancer and classified as high risk according to the European Association of Urology 2020 version of the Non-Muscle Invasive Bladder Cancer Guidelines.
  4. Patients who had failed intravesical administration of BCG prior to enrolment and were not candidates for or refused radical cystectomy.BCG failures included BCG , recurrence after BCG, BCG non-responsive, and BCG intolerant;
  5. After TURBT, it is confirmed that the tumour has been completely removed from the bladder. A second TURBT is required for the following: confirmed or suspected incomplete resection of the tumour by TURBT; absence of muscularis propria tissue in the first resection of the tumour specimen, except for TaLG/G1 tumours or primary carcinoma in situ; and stage T1 bladder tumours. A second TURBT is recommended 2 to 6 weeks after the initial TURBT.
  6. (ECOG) score 0 to 1.
  7. Expected survival ≥ 6 months.
  8. The major organs are functioning well, i.e. the following criteria are met:

    • Bone marrow function: (HGB) ≥80 g/L, count (PLT) ≥100×109/L, (ANC) ≥1.5×109/L.
    • Liver function: serum total ≤ 1.25 x (ULN) (or 2.5 × ULN in case of constitutional hepatic dysfunction jaundice [Gilbert's syndrome]), (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN.
    • Renal function: ≥30 mL/min (Cockcroft-Gault formula) or serum creatinine ≤2.0 mg/dL.

Exclusion criteria

Exclusion Criteria:

  1. Patients with muscle-invasive bladder cancer (T2-T4).
  2. Patients with urothelial carcinoma of the upper or lower urinary tract, and/or lymph node .
  3. Patients with a history of vesicoureteral reflux.
  4. Patients with other within 2 years, except locally curable (cured) cancers, e.g. basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix.
  5. Patients who have not recovered (toxicity assessment remains > Grade 1 or has not recovered to baseline levels) from toxic reactions (other than malaise, alopecia) associated with prior antineoplastic therapy; patients who have not recovered to Grade 0-1 ( 5.0) within 3 days prior to the first dose for the following: uncontrolled acute and chronic infections, e.g., pneumonitis, biliary tract infections, virus infections, and virus infections; Respiratory distress; acute and chronic kidney injury; nephrotic syndrome; bladder perforation; urinary tract obstruction.
  6. Patients with severe or uncontrolled cardiac disease requiring treatment, including: a) severe arrhythmias (ventricular arrhythmias requiring clinical intervention, degree II-III atrioventricular block, etc.); b) history of myocardial infarction, unstable angina pectoris, angioplasty, or coronary artery bridging surgery within 6 months prior to the first dose of the study drug; c) (NYHA) class III or IV congestive heart failure (see Appendix 4); d) 12-lead electrocardiography: corrected : QTc > 450 ms in men and QTc > 470 ms in women (QTc intervals were calculated using the Fridericia formula).
  7. Patients with uncontrolled hypertension on treatment (defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg).
  8. Patients with peripheral neuropathy > grade 1.
  9. Patients with known or suspected to docetaxel, its or similar drugs.
  10. Patients previously treated with docetaxel.
  11. Patients with previous extensive radiotherapy to the pelvis (radiotherapy > 30% of the bone marrow area).
  12. Patients who have undergone major surgical treatment within 28 days prior to the first dose, or who have failed to recover to ≤ grade 2 from adverse effects of any such procedure.
  13. Patients who have received intravesical therapy within 28 days prior to the first dose (immediate chemotherapy infusion after previous and current electrodes is permitted).
  14. Patients receiving antitumor therapy such as chemotherapy, radiotherapy, targeted therapy, immunotherapy, biologic therapy, and herbal medicine within 28 days or 5 half-lives of the drug, whichever is longer, prior to the first dose.
  15. Patients who have participated in any other clinical interventional trial treatment (other than patients enrolled in a study with overall survival follow-up) within 28 days or 5 half-lives, whichever is longer, prior to the first dose.
  16. Patients who plan to receive other anticancer treatments or other drugs during the study period.
  17. Pregnant or breastfeeding female patients. Positive blood pregnancy test in females of within 7 days prior to first dose; Any male and female patient of childbearing potential refuses to use a method with an annual failure rate of \<1% (contraceptive methods with an annual failure rate of \<1% include bilateral tubal ligation, male sterilization, proper use of hormonal contraceptives that suppress ovulation, hormone-releasing intrauterine devices (IUDs), and copper-containing IUDs, or condoms) throughout the duration of the trial and for a period of 30 days after the last study dose. In the judgment of the investigators, a patient is defined as having the ability to procreate as he/she is biologically capable of having children as well as having a normal sex life. Female patients who are not of childbearing potential (i.e., meet at least 1 of the following criteria):

    • Has had a hysterectomy or bilateral oophorectomy, or
    • Medically diagnosed with ovarian failure, or
    • Medically diagnosed as (menopause for at least 12 consecutive months in the absence of pathologic or physiologic causes).
  18. Patients with known history of psychiatric disorders, substance abuse, drug and alcohol addiction, and impairments in adherence.
  19. Any other patients who, in the opinion of the investigator, would result in unnecessary risk to the subject and are therefore unsuitable for participation in this clinical study.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    BH011

    BH011 is administered intravesically through a urinary catheter and is retained in the bladder for 1 hour.

    Drug: BH011

Interventions

  • DrugBH011

    BH011 is administered intravesically through a urinary catheter and is retained in the bladder for 1 hour. It was administered once a week for 6 weeks during the induction treatment period and once a month for 12 months during the maintenance treatment period.

    Also known as: Docetaxel

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events

    Adverse events will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.

    Time frame: From first dose to 30 days after last dose

  2. 3 month Complete Response Rate (CRR)

    Complete Response rate is defined as the percentage of participants achieving a CR at 3 months post-treatment. It will be measured by determining the percentage of participants without presence of high-grade disease using results from cystoscopy and urine cytology at any time point.

    Time frame: 3 months

Secondary outcomes

  1. 6 month Complete Response Rate (CRR)

    Complete Response rate is defined as the percentage of participants achieving a CR at 6 months post-treatment. It will be measured by determining the percentage of participants without presence of high-grade disease using results from cystoscopy and urine cytology at any time point.

    Time frame: 6 months

  2. Recurrence-Free Survival (RFS)

    RFS is defined as the time from the first study treatment to the presentation of the first pathologically confirmed high-risk non-muscle invasive bladder cancer (T1, CIS, or high-grade Ta) recurrence or death from any cause, whichever occurred earliest.

    Time frame: up to 24 months

  3. Progression-Free Survival (PFS)

    PFS is defined as the time from the first study treatment to the occurrence of the first bladder cancer infiltration into the muscularis propria, lymphatic metastasis, distant metastasis, or death from any cause, whichever occurred earliest.

    Time frame: up to 24 months

  4. Recurrence-Free Survival Rate

    The RFS rate is defined as the rate of subjects without pathologically confirmed high-risk non-muscle invasive bladder cancer (T1, CIS, or high-grade Ta) recurrence or death from any cause.

    Time frame: up to 24 months

  5. Progression-Free Survival Rate

    The PFS rate is defined as the rate of subjects free of bladder cancer infiltration into the muscularis propria, lymphatic metastasis, distant metastasis, or death from any cause.

    Time frame: up to 24 months

  6. Pharmacokinetic of BH011

    Maximum Concentration (Cmax)

    Time frame: Weeks 1 and 6 of dosing

  7. Pharmacokinetic of BH011

    Time to Cmax (Tmax)

    Time frame: Weeks 1 and 6 of dosing

  8. Pharmacokinetic of BH011

    Area Under the Curve From Time 0 Hours to Last Quantifiable Concentration (AUC0-last)

    Time frame: Weeks 1 and 6 of dosing

  9. Pharmacokinetic of BH011

    Area Under the Curve From Time 0 Hours to Infinity (AUC0-inf)

    Time frame: Weeks 1 and 6 of dosing

  10. Pharmacokinetic of BH011

    Apparent Terminal Elimination Half-Life (t1/2)

    Time frame: Weeks 1 and 6 of dosing

  11. Pharmacokinetic of BH011

    Apparent Total Clearance (CL)

    Time frame: Weeks 1 and 6 of dosing

  12. Pharmacokinetic of BH011

    Apparent Volume of Distribution (Vz/F)

    Time frame: Weeks 1 and 6 of dosing

07

Study locations

3 of 6 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Dec 2025, 40 months after the start.

Of 39 industry-sponsored phase 1/2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 74. This study's planned 40 months is below that.

Counting every sponsor, half of 67 studies reached it within 52 months; a quarter within 35 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 9, 2024
First posted
Dec 13, 2024
StartActual
Aug 3, 2022
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Jan 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06732531
Lead sponsor
Zhuhai Beihai Biotech Co., Ltd
Responsible party
Sponsor
First posted
Dec 13, 2024
Start date
Aug 3, 2022
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Jan 9, 2025

Study contacts

Xiaohua Wei
Contact
xhwei@bayhibiotech.com
+86 756 6349669
Xiaohua Wei
study director · Zhuhai Beihai Biotech Co., Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Docetaxel

Start the discussion